StocksMediumUpdated•Originally published 4 November 2026•Updated 4 November 2026•
1 min read
STERIS Beats Q2 Earnings and Revenue Estimates, Raises Full-Year Guidance
Key Facts
1STERIS total revenue increased 9% to $1.6 billion in the second quarter of fiscal 2027.
2Constant currency organic revenue growth was 8% for the quarter ended September 30, 2026.
STERIS reported adjusted earnings per share of $2.94 for the fiscal second quarter, beating analyst estimates by $0.26. GlobeNewswire reported that total revenue increased 9% to $1.6 billion, exceeding expectations by $40 million for the quarter ended September 30, 2026.
STE closed at $231.35 on November 3, 2026, as results showed constant currency organic revenue growth of 8%. The Life Sciences segment saw an 18% revenue increase to $170.6 million, while Healthcare segment sales grew 9% to $1.1 billion. Following the performance, the company raised its full-year adjusted earnings guidance to a range of $11.35 to $11.55 per share.